Ionis Pharmaceuticals Reports Statistically Significant Data

Ionis Pharmaceuticals said Wednesday a phase 2 study showed that patients with type 2 diabetes uncontrolled on stable, maximal metformin therapy treated with IONIS-GCGR achieved robust and sustained, statistically significant improvements in hemoglobin A1c and other measures of glucose control after 26 weeks of treatment.

“”Based on the profile we observed in this study, including substantial HbA1c lowering and favorable safety, we have identified an optimal dose to advance to a large pivotal program,” said Richard Geary, senior VP of clinical development. “We are now evaluating partnership opportunities for IONIS-GCGRRx and are excited with the prospect of moving this potential novel treatment forward.”

The company said that the primary goal of the phase 2 study was to identify a dose that produced robust HbA1c reductions without triggering previously observed on-target liver enzyme elevations or other off-target side effects observed with small molecule inhibitors of GCGR, such as increases in LDL-cholesterol and blood pressure.

Leave a Comment